Back to top

Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corporate executives informed on what's moving stocks. Sign up for a free trial at thefly.com to see what Wall Street is buzzing about.

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Instil Bio, Inc. (TIL)